Pressure Ulcers – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Pressure Ulcers – Pipeline Review, H1 2017’, provides an overview of the Pressure Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pressure Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pressure Ulcers

The report reviews pipeline therapeutics for Pressure Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pressure Ulcers therapeutics and enlists all their major and minor projects

The report assesses Pressure Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pressure Ulcers

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pressure Ulcers

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pressure Ulcers pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pressure Ulcers - Overview

Pressure Ulcers - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Pressure Ulcers - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pressure Ulcers - Companies Involved in Therapeutics Development

EyeGene Inc

Izun Pharmaceuticals Corp

MediWound Ltd

NovaLead Pharma Pvt Ltd

RegeneRx Biopharmaceuticals Inc

RMB-Research GmbH

Pressure Ulcers - Drug Profiles

AG-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-Decorin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EscharEx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IZN-6D4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLP-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Statmicoll - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Pressure Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pressure Ulcers - Dormant Projects

Pressure Ulcers - Discontinued Products

Pressure Ulcers - Product Development Milestones

Featured News & Press Releases

Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 2016

Dec 04, 2015: RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results

Sep 22, 2008: RegeneRx/Sigma-Tau Completes Patient Enrollment Of Second Phase II Clinical Trial With RGN-137

Aug 20, 2008: RegeneRx Completes Patient Enrollment Of First Phase II Clinical Trial

Nov 02, 2004: RegeneRx Gets Cleared To Initiate Phase II Clinical Trial With Tß4 For Chronic Pressure Ulcers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pressure Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pressure Ulcers – Pipeline by EyeGene Inc, H1 2017

Pressure Ulcers – Pipeline by Izun Pharmaceuticals Corp, H1 2017

Pressure Ulcers – Pipeline by MediWound Ltd, H1 2017

Pressure Ulcers – Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Pressure Ulcers – Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017

Pressure Ulcers – Pipeline by RMB-Research GmbH, H1 2017

Pressure Ulcers – Dormant Projects, H1 2017

Pressure Ulcers – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Pressure Ulcers, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports